Anticoagulant therapy with DOACs may reduce cardiovascular risk factors in the development of the AD-related dementias, whereas inhibitors of AChE and/or BChE may restore the cholinergic transmission in the AD brain at different disease stages. The gene discussed is BCHE; the disease is dementia.